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Traditionally, thyroid carcinoma has been subdi- 
vided into differentiated (papillary; mixed papil- 
lary/follicular, follicular, Hurthle cell, clear cell, 
and medullary) and undifferentiated (anaplastic) 
types. It is generally believed that differentiated 
thyroid carcinoma can be divided into 2 histogeneti- 
cally distinct categories, follicular and papillary 
carcinoma, which are derived from follicular cells 
and are associated with the production of thyro- 
globulin and thyroid hormones; and medullary car- 
cinoma, which is derived from the parafollicular 
cells (C cells) and is associated with the production 
of calcitonin and other peptide hormones. The 
number of case reports of mixed thyroid carcino- 
mas of medullary, papillary, follicular, and undiffer- 
entiated patterns in both the primary and metastatic 
lesions has been increasing in the literature [1-5]. 
Ljungberg and co-workers from Sweden have 
demonstrated by histologic, histochemical, and 
radioimmunologic techniques that both follicular 
and parafollicular cells can exist in a mixed neo- 
plasm [2]. They also showed uptake of 131I by 
pulmonary metastases in their reported case. Hell- 
man and co-workers reported in 1979 the successful 
treatment with ~31I of a 16-year-old girl with residual 
medullary carcinoma following a near-total thyroid- 
ectomy [6]. They demonstrated a clear decrease in 
thyrocalcitonin levels to normal levels after ~3~I 
therapy. These authors believe that normal thyroid 
tissue trapped the 13~I and delivered approximately 
34,000 rad to the tumor bed destroying not only the 
remaining normal follicular cells but also the 
parafollicular cells (medullary cancer). 
The 2 cases of ~3JI uptake in medullary cancers 
reported in this article probably represent the mixed 
pattern of follicular and parafollicular tumors pre- 
viously described. The authors, however, have not 
provided any evidence of the histologic appearance 
of the metastases in their 2 cases (P.J. and R.M.) 
with 131I uptake. In the 2 cases (M.L., Fig. 2 and 
H.J., Fig. 3) in which excised lymph nodes demon- 
strated only metastatic medullary carcinoma, there 
was no 131I uptake. Their first case (G.S.) of mixed 
"anaplastic" and medullary carcinoma appears to 
be another example of a mixed tumor. Parker and 
colleagues demonstrated, by histological studies 
and immunoperoxidase staining for calcitonin and 
thyroglobulin, the presence of both follicular and 
medullary areas in tumor metastatic to lymph nodes 
from a patient whose primary thyroid neoplasm was 
medullary carcinoma [1]. 
In order to state that medullary carcinoma con- 
centrates ~3~1, areas of follicular cells must first be 
absolutely excluded since they are the areas of 
probable uptake of ~31I. Riccabona and colleagues 
have failed to satisfy this important criterion. 
There will be an increasingly small number of 
patients with residual or metastatic medullary car- 
cinoma who will benefit from therapeutic ~3~I. To 
determine which patients can be treated with ~31I 
will require more routine postoperative scanning 
with ~3~I in all cases of medullary carcinoma, as well 
as careful examination of all excised tissue for the 
mixed follicular and parafollicular tumor pattern. 
Immunolocalization techniques using calcitonin and 
thyroglobulin are essential for accurate diagnosis of 
these thyroid carcinomas. 
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